1201645-46-6

Basic information

• Product Name: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetamide
• Synonyms: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetamide;N-[5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]-acetamide;5-(Acetamido)pyridine-3-boronic acid pinacol ester;N-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl);(5-ACETAMIDOPYRIDIN-3-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 1201645-46-6
• Molecular Formula: C₁₃H₁₉BN₂O₃
• Molecular Weight: 262.11256
• EINECS: 1592732-453-0
• Mol File: 1201645-46-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 441.8±30.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.11±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.30±0.70(Predicted)
• CAS DataBase Reference: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetamide(1201645-46-6)
• EPA Substance Registry System: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetamide(1201645-46-6)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 1201645-46-6(Hazardous Substances Data)

Usage

General Description

N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetamide is a complex organic compound that belongs to the class of chemical entities known as organoboron compounds. Organoboron compounds contain a chemical group composed of boron linked to one or more organic groups. N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetamide, in particular, is structured with boron bound to two oxygen atoms and a pyridine group, along with acetic acid amide and tetramethyl groups. The specific properties and reactivity of this compound would be influenced by the presence of boron and these functional groups, making it of interest in various chemical research and synthesis applications. However, further detailed information regarding its physical properties, applications, and safety information are not readily or widely available, suggesting that it is relatively specialty or niche in its use.

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 15862-46-1 N-(5-bromo-pyridin-3-yl)-acetamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1201646-57-2 N-(5-(3-benzyl-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-3-yl)acetamide 
• 1201646-59-4 N-(5-(2-benzyl-2H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-3-yl)acetamide 
• 1201646-60-7 N-(5-(3-benzyl-1-(4-cyanophenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-3-yl)acetamide 
• 1201646-58-3 N-(5-(3-benzyl-1-bromo-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-3-yl)acetamide 

Relevant articles and documents

A universal acetyl-aminopyridine boric acid frequency alcohol ester preparation method

The invention belongs to the field of organic compound synthesis and provides a preparation method of commonly used acetamidopyridine boronic acid pinacol ester. The preparation method comprises the following steps: 1. with halogenated aminopyridine as a starting material, reacting with acetic anhydride in dichloromethane to obtain halogenated acetamidopyridine; and 2. with dioxane as a solvent, mixing the halogenated acetamidopyridine, potassium acetate and bis(pinacolato)diboron under the protection of nitrogen and adding a catalyst ferrocene palladium chloride to react at 60-100 DEG C for 18-24 hours, thus generating the acetamidopyridine boronic acid pinacol ester. The raw materials are convenient to directly purchase from the markets. The preparation method is simple, is convenient to operate, is high in yield and is convenient for industrial production.

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.